Status:
COMPLETED
Effect of Candesartan in Alcoholic Liver Fibrosis
Lead Sponsor:
Yonsei University
Conditions:
Alcoholic Liver Disease
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
PHASE2
Brief Summary
Background: Alcohol is one of principal causes of hepatic fibrosis. Although the most effective treatment for alcoholic hepatic fibrosis is abstinence of alcohol consumption, additive treatment to re...
Eligibility Criteria
Inclusion
- Clinical diagnosis of alcoholic liver disease
- METAVIR fibrosis score ≥ 2 in liver biopsy
- Alcohol intake has stop during at least 6 months until study enrollment
Exclusion
- Hepatocellular carcinoma or other malignancy
- Clinically decompensated cirrhosis (Total bilirubin ≥ 5mg/dL or variceal hemorrhage or ascites development or hepatic encephalopathy developement)
- Chronic liver disease related with other causes except alcohol
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
85 Patients enrolled
Trial Details
Trial ID
NCT00990639
Start Date
September 1 2005
End Date
March 1 2009
Last Update
October 7 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yonsei University Wonju College of Medicine Wonju Christian Hospital
Wŏnju, Gangwon-do, South Korea, 220-701